Compare JYNT & BDSX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | JYNT | BDSX |
|---|---|---|
| Founded | 2010 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Multi-Sector Companies | Precision Instruments |
| Sector | Miscellaneous | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 120.7M | 107.5M |
| IPO Year | 2014 | 2020 |
| Metric | JYNT | BDSX |
|---|---|---|
| Price | $8.87 | $9.96 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 5 |
| Target Price | $17.00 | ★ $32.50 |
| AVG Volume (30 Days) | 28.5K | ★ 48.1K |
| Earning Date | 05-07-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 133.93 | N/A |
| EPS | ★ 0.19 | N/A |
| Revenue | ★ $117,696,356.00 | $88,499,000.00 |
| Revenue This Year | $12.23 | $25.26 |
| Revenue Next Year | N/A | $19.15 |
| P/E Ratio | $47.68 | ★ N/A |
| Revenue Growth | 15.49 | ★ 24.08 |
| 52 Week Low | $7.50 | $0.25 |
| 52 Week High | $13.47 | $20.21 |
| Indicator | JYNT | BDSX |
|---|---|---|
| Relative Strength Index (RSI) | 51.96 | 31.06 |
| Support Level | $8.01 | $6.00 |
| Resistance Level | $9.05 | $11.57 |
| Average True Range (ATR) | 0.33 | 1.01 |
| MACD | 0.01 | -0.33 |
| Stochastic Oscillator | 39.77 | 10.92 |
The Joint Corp develops, owns, operates, supports, and manages chiropractic clinics through direct ownership, management arrangements, franchising, and the sales of regional developer rights throughout the United States. The doctors of chiropractic develop personalized treatment plans to relieve patients' pain and deliver ongoing preventative care. The company has one operating business segment; The Franchise Operations segment, which is comprised of the operating activities of the franchise business unit. The Franchise Operations segment derives revenue from customers by providing access to the company's franchise license, which represents symbolic intellectual property.
Biodesix Inc is a diagnostic solutions company with a focus on lung disease. The Company has a single operating segment focused on providing diagnostic testing services to customers. It provides biopharmaceutical companies with services that include diagnostic research, clinical trial testing, and the discovery, development, and commercialization of companion diagnostics. The revenue is derived from two sources: providing diagnostic testing services associated with blood-based lung and COVID tests; and providing biopharmaceutical companies with services generally provided outside the clinical setting and governed by individual contracts with third parties, as well as the development and commercialization of companion diagnostics.